{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T14:36:52Z","timestamp":1776695812439,"version":"3.51.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1245\/s10434-020-09112-2","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T13:14:36Z","timestamp":1599743676000},"page":"5240-5247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Multidisciplinary Care for Melanoma of Unknown Primary: Experience in the Era of Molecular Profiling"],"prefix":"10.1245","volume":"27","author":[{"given":"James P.","family":"De Andrade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishwas","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arya","family":"Amini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans F.","family":"Schoellhammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim A.","family":"Margolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Afkhami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6279-7981","authenticated-orcid":false,"given":"Laleh G.","family":"Melstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,9]]},"reference":[{"key":"9112_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330. https:\/\/doi.org\/10.3322\/caac.21590. PubMed PMID: 31912902.","journal-title":"CA Cancer J Clin."},{"key":"9112_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.critrevonc.2010.04.007","volume":"78","author":"K Kamposioras","year":"2011","unstructured":"Kamposioras K, Pentheroudakis G, Pectasides D, Pavlidis N. Malignant melanoma of unknown primary site: to make the long story short: a systematic review of the literature. Crit Rev Oncol Hematol. 2011;78:112\u201326. https:\/\/doi.org\/10.1016\/j.critrevonc.2010.04.007. PubMed PMID: 20570171.","journal-title":"Crit Rev Oncol Hematol."},{"key":"9112_CR3","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/pcmr.12153","volume":"26","author":"K Dutton-Regester","year":"2013","unstructured":"Dutton-Regester K, Kakavand H, Aoude LG, Stark MS, Gartside MG, Johansson P, et al. Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. Pigment Cell Melanoma Res. 2013;26:852\u201360. https:\/\/doi.org\/10.1111\/pcmr.12153. PubMed PMID: 23890154.","journal-title":"Pigment Cell Melanoma Res."},{"key":"9112_CR4","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/cncr.21835","volume":"106","author":"JN Cormier","year":"2006","unstructured":"Cormier JN, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE, et al. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer. 2006;106:2012\u201320. https:\/\/doi.org\/10.1002\/cncr.21835. PubMed PMID: 16568458.","journal-title":"Cancer."},{"key":"9112_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34. https:\/\/doi.org\/10.1186\/s13073-017-0424-2. PubMed PMID: 28420421; PubMed Central PMCID: PMCPMC5395719.","journal-title":"Genome Med."},{"key":"9112_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334. https:\/\/doi.org\/10.1056\/nejmoa1504030. PubMed PMID: 26027431; PubMed Central PMCID: PMCPMC5698905.","journal-title":"N Engl J Med."},{"key":"9112_CR7","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867\u201376. https:\/\/doi.org\/10.1056\/nejmoa1408868. PubMed PMID: 25265494.","journal-title":"N Engl J Med."},{"key":"9112_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30\u20139. https:\/\/doi.org\/10.1056\/nejmoa1412690. PubMed PMID: 25399551.","journal-title":"N Engl J Med."},{"key":"9112_CR9","doi-asserted-by":"publisher","unstructured":"Anbari KK, Schuchter LM, Bucky LP, Mick R, Synnestvedt M, Guerry DT, et al. Melanoma of unknown primary site: presentation, treatment, and prognosis: a single-institution study. University of Pennsylvania Pigmented Lesion Study Group. Cancer. 1997;79:1816\u201321. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19970501)79:9%3c1816::aid-cncr26%3e3.0.co;2-#. PubMed PMID: 9129001.","DOI":"10.1002\/(sici)1097-0142(19970501)79:9%3c1816::aid-cncr26%3e3.0.co;2"},{"key":"9112_CR10","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1007\/s12032-012-0217-9","volume":"29","author":"R Clerico","year":"2012","unstructured":"Clerico R, Bottoni U, Paolino G, Ambrifi M, Corsetti P, Devirgiliis V, et al. Melanoma with unknown primary: report and analysis of 24 patients. Med Oncol. 2012;29:2978\u201384. https:\/\/doi.org\/10.1007\/s12032-012-0217-9. PubMed PMID: 22460835.","journal-title":"Med Oncol."},{"key":"9112_CR11","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ejca.2012.09.005","volume":"49","author":"AC de Waal","year":"2013","unstructured":"de Waal AC, Aben KK, van Rossum MM, Kiemeney LA. Melanoma of unknown primary origin: a population-based study in the Netherlands. Eur J Cancer. 2013;49:676\u201383. https:\/\/doi.org\/10.1016\/j.ejca.2012.09.005. PubMed PMID: 23031553.","journal-title":"Eur J Cancer."},{"key":"9112_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/00008390-200502000-00013","volume":"15","author":"KA Katz","year":"2005","unstructured":"Katz KA, Jonasch E, Hodi FS, Soiffer R, Kwitkiwski K, Sober AJ, et al. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res. 2005;15:77\u201382. https:\/\/doi.org\/10.1097\/00008390-200502000-00013. PubMed PMID: 15714125.","journal-title":"Melanoma Res."},{"key":"9112_CR13","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1159\/000453592","volume":"232","author":"S Ribero","year":"2016","unstructured":"Ribero S, Pampena R, Bataille V, Moscarella E, Thomas L, Quaglino P, et al. Unknown primary melanoma: worldwide survey on clinical management. Dermatology. 2016;232:704\u20137. https:\/\/doi.org\/10.1159\/000453592. PubMed PMID: 28052277.","journal-title":"Dermatology."},{"key":"9112_CR14","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1634\/theoncologist.2015-0522","volume":"21","author":"D Kuk","year":"2016","unstructured":"Kuk D, Shoushtari AN, Barker CA, Panageas KS, Munhoz RR, Momtaz P, et al. Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis. Oncologist. 2016;21:848\u201354. https:\/\/doi.org\/10.1634\/theoncologist.2015-0522. PubMed PMID: 27286787; PubMed Central PMCID: PMC4943393.","journal-title":"Oncologist."},{"key":"9112_CR15","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1524-4725.2010.01562.x","volume":"36","author":"P Rutkowski","year":"2010","unstructured":"Rutkowski P, Nowecki ZI, Dziewirski W, Zdzienicki M, Pienkowski A, Salamacha M, et al. Melanoma without a detectable primary site with metastases to lymph nodes. Dermatol Surg. 2010;36:868\u201376. https:\/\/doi.org\/10.1111\/j.1524-4725.2010.01562.x. PubMed PMID: 20482725.","journal-title":"Dermatol Surg."},{"key":"9112_CR16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/jso.25302","volume":"119","author":"Y Song","year":"2019","unstructured":"Song Y, Karakousis GC. Melanoma of unknown primary. J Surg Oncol. 2019;119:232\u201341. https:\/\/doi.org\/10.1002\/jso.25302. PubMed PMID: 30481368.","journal-title":"J Surg Oncol."},{"key":"9112_CR17","first-page":"341","volume":"117","author":"T Dasgupta","year":"1963","unstructured":"Dasgupta T, Bowden L, Berg JW. Malignant melanoma of unknown primary origin. Surg Gynecol Obstet. 1963;117:341\u20135. PubMed PMID: 14080349.","journal-title":"Surg Gynecol Obstet."},{"key":"9112_CR18","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1245\/s10434-014-3799-y","volume":"21","author":"A Gos","year":"2014","unstructured":"Gos A, Jurkowska M, van Akkooi A, Robert C, Kosela-Paterczyk H, Koljenovic S, et al. Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site. Ann Surg Oncol. 2014;21:4317\u201323. https:\/\/doi.org\/10.1245\/s10434-014-3799-y. PubMed PMID: 24866436; PubMed Central PMCID: PMC4218979.","journal-title":"Ann Surg Oncol."},{"key":"9112_CR19","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/jso.21994","volume":"104","author":"T Tos","year":"2011","unstructured":"Tos T, Klyver H, Drzewiecki KT. Extensive screening for primary tumor is redundant in melanoma of unknown primary. J Surg Oncol. 2011;104:724\u20137. https:\/\/doi.org\/10.1002\/jso.21994. PubMed PMID: 21721009.","journal-title":"J Surg Oncol."},{"key":"9112_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/(sici)1097-0142(19970701)80:1<60::aid-cncr8>3.0.co;2-j","volume":"80","author":"B Schlagenhauff","year":"1997","unstructured":"Schlagenhauff B, Stroebel W, Ellwanger U, Meier F, Zimmermann C, Breuninger H, et al. Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. Cancer. 1997;80:60\u20135. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19970701)80:1%3c60::aid-cncr8%3e3.0.co;2-j. PubMed PMID: 9210709.","journal-title":"Cancer."},{"key":"9112_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/annonc\/mdt411","volume":"25","author":"F Egberts","year":"2014","unstructured":"Egberts F, Bergner I, Kruger S, Haag J, Behrens HM, Hauschild A, et al. Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas. Ann Oncol. 2014;25:246\u201350. https:\/\/doi.org\/10.1093\/annonc\/mdt411. PubMed PMID: 24276025.","journal-title":"Ann Oncol."},{"key":"9112_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaad.2014.09.029","volume":"72","author":"JM Bae","year":"2015","unstructured":"Bae JM, Choi YY, Kim DS, Lee JH, Jang HS, Lee JH, et al. Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2015;72:59\u201370. https:\/\/doi.org\/10.1016\/j.jaad.2014.09.029. PubMed PMID: 25440435.","journal-title":"J Am Acad Dermatol."},{"key":"9112_CR23","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1200\/JCO.2008.18.9845","volume":"27","author":"CC Lee","year":"2009","unstructured":"Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol. 2009;27:3489\u201395. https:\/\/doi.org\/10.1200\/jco.2008.18.9845. PubMed PMID: 19451446; PubMed Central PMCID: PMC2717755.","journal-title":"J Clin Oncol."},{"key":"9112_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000478050","volume":"93","author":"K Utter","year":"2017","unstructured":"Utter K, Goldman C, Weiss SA, Shapiro RL, Berman RS, Wilson MA, et al. Treatment outcomes for metastatic melanoma of unknown primary in the new era: a single-institution study and review of the literature. Oncology. 2017;93:249\u201358. https:\/\/doi.org\/10.1159\/000478050. PubMed PMID: 28746931; PubMed Central PMCID: PMC5617794.","journal-title":"Oncology."},{"key":"9112_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/ijc.32229","volume":"146","author":"D Verver","year":"2020","unstructured":"Verver D, van der Veldt A, van Akkooi A, Verhoef C, Grunhagen DJ, Louwman WJ. Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: a Dutch population-based study. Int J Cancer. 2020;146:26\u201334. https:\/\/doi.org\/10.1002\/ijc.32229. PubMed PMID: 30801710; PubMed Central PMCID: PMC6900034.","journal-title":"Int J Cancer."},{"key":"9112_CR26","doi-asserted-by":"publisher","first-page":"e1677139","DOI":"10.1080\/2162402X.2019.1677139","volume":"8","author":"T Gambichler","year":"2019","unstructured":"Gambichler T, Chatzipantazi M, Schroter U, Stockfleth E, Gedik C. Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results. Oncoimmunology. 2019;8:e1677139. https:\/\/doi.org\/10.1080\/2162402x.2019.1677139. PubMed PMID: 31741779; PubMed Central PMCID: PMC6844308.","journal-title":"Oncoimmunology."},{"key":"9112_CR27","unstructured":"Lee CC, Faries MB, Morton DL. Management decisions for nodal metastasis from an unknown primary melanoma. Am J Hematol Oncol. 2008;7:306\u20138. PubMed PMID: 21687815; PubMed Central PMCID: PMC3115657."},{"key":"9112_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1200\/JCO.2007.14.0285","volume":"26","author":"CC Lee","year":"2008","unstructured":"Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol. 2008;26:535\u201341. https:\/\/doi.org\/10.1200\/jco.2007.14.0285. PubMed PMID: 18235114.","journal-title":"J Clin Oncol."},{"key":"9112_CR29","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1245\/s10434-011-1801-5","volume":"18","author":"SP Prens","year":"2011","unstructured":"Prens SP, van der Ploeg AP, van Akkooi AC, van Montfort CA, van Geel AN, de Wilt JH, et al. Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site. Ann Surg Oncol. 2011;18:3586\u201392. https:\/\/doi.org\/10.1245\/s10434-011-1801-5. PubMed PMID: 21611857; PubMed Central PMCID: PMC3222814.","journal-title":"Ann Surg Oncol."},{"issue":"258\u201365","key":"9112_CR30","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.jaad.2018.03.021","volume":"79","author":"JF Scott","year":"2018","unstructured":"Scott JF, Conic RZ, Thompson CL, Gerstenblith MR, Bordeaux JS. Stage IV melanoma of unknown primary: a population-based study in the United States from 1973 to 2014. J Am Acad Dermatol. 2018;79:258\u201365 e4. https:\/\/doi.org\/10.1016\/j.jaad.2018.03.021. PubMed PMID: 29580859; PubMed Central PMCID: PMC6050094.","journal-title":"J Am Acad Dermatol."},{"key":"9112_CR31","doi-asserted-by":"publisher","unstructured":"Sirvan SS, Ihsan Eren H, Kurt Yazar S, Gunenc AC, Yesilada AK, Irmak F, et al. Approach to patients with malignant melanoma of unknown primary origin. Sisli Etfal Hastanesi Tip Bulteni. 2019;53:125\u201331. https:\/\/doi.org\/10.14744\/semb.2019.52333. PubMed PMID: 32377070; PubMed Central PMCID: PMC7199841.","DOI":"10.14744\/semb.2019.52333"},{"key":"9112_CR32","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1245\/s10434-014-3679-5","volume":"21","author":"AP van der Ploeg","year":"2014","unstructured":"van der Ploeg AP, Haydu LE, Spillane AJ, Scolyer RA, Quinn MJ, Saw RP, et al. Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease. Ann Surg Oncol. 2014;21:3108\u201316. https:\/\/doi.org\/10.1245\/s10434-014-3679-5. PubMed PMID: 24802907.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09112-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-09112-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09112-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T23:12:01Z","timestamp":1631142721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-09112-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,9]]},"references-count":32,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["9112"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-09112-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,9]]},"assertion":[{"value":"13 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Vishwas Parekh is a consultant for Genentech, Inc. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}